Image shows a female doctor or pharmacist having a discussion with her patient.
Ready to vaccinate with SHINGRIX▼ (herpes zoster vaccine, recombinant, adjuvanted)?

Get the information you need to administer SHINGRIX to adults 50 years of age and older with confidence.1,2

SHINGRIX reconstitution instructions

Follow these instructions when reconstituting and administering SHINGRIX to your patients 50 years of age and older.1,2

SHINGRIX vaccine MUST be reconstituted prior to administration.1,2

Prescribing information (GB)

Prescribing information (NI)

Dosing and administration

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1,2

Making it part of your routine

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1,2

SHINGRIX vaccine MUST be reconstituted prior to administration.1,2

Ensuring two-dose schedule completion

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1,2

Red medical information card icon
  • SHINGRIX list price: £160
  • SHINGRIX can be purchased from AAH Pharmaceuticals or Alliance Healthcare (Distribution) Ltd.

For more information on SHINGRIX, contact a GSK representative.

Learn more about SHINGRIX

References

  1. Shingrix, GB Summary of Product Characteristics (SPC)
  2. Shingrix, NI Summary of Product Characteristics (SPC)
  3. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009 137 38-472.
  4. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  5. UK NICE Clinical Knowledge Summaries. What are the complications? October 2020. Accessed July 2021.
  6. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  7. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  8. DH Green Book ch 28a - Shingles. February 2016. Accessed July 2021.
  9. Public Health England Green Book. Immunisation Procedures Chapter 4. Jun 2012.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

PM-GB-SGX-WCNT-210011
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.